Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Alnylam
Company Location: Eastern America
Company Founding Year: 2002
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07535606 |
ALN-4915-001 | P1 |
Recruiting |
Healthy Volunteers |
2027-07-31 |
88% |
2026-04-23 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|